Risk factor
Very poor trading liquidity
Profitability factor
Undervalued vs peers
About
Welgene Biotech Co.,Ltd. primarily focuses on delivering genetic analysis services. The company provides comprehensive support for scientific research, employing a range of advanced laboratory techniques such as genetic sequencing, microarray analysis, qPCR verification, nucleic acid extraction and quality control, LCM single cell experimentation, and intricate bioinformatics analysis. A key offering in their portfolio is Cytoscan, an array-based comparative genomic hybridization (CGH) solution. Beyond services, Welgene Biotech also supplies essential laboratory products, including various reagents, consumable items, and specialized instruments, alongside dedicated software solutions. Established in 2003, the company operates from its headquarters in Taipei City, Taiwan.
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. In particular, the stock is 'expensive' on EV/EBITDA, undervalued on P/FC.